PANDOX AB |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.02 EUR | 0.00% |
|
+5.26% | +36.00% |
| Jul. 12 | Transcript : Pandox AB, H1 2024 Earnings Call, Jul 12, 2024 | |
| Jul. 12 | Pandox AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 | CI |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company is highly valued given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Real Estate Development & Operations
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +36.00% | 3.62B | - | ||
| +32.82% | 27.28B | B- | ||
| -16.64% | 25.27B | B | ||
| -5.18% | 24.71B | B- | ||
| +16.16% | 24.68B | A- | ||
| +34.48% | 21.2B | A- | ||
| +2.40% | 19.49B | B- | ||
| -3.34% | 18.9B | A | ||
| +42.64% | 17.42B | B+ | ||
| +19.53% | 15.27B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PNDX B Stock
- POX Stock
- Ratings Pandox AB
